Momentum Biotechnologies’ Post

Can you go from idea to drug candidate in one year? At Gubra, we constantly pursue novel approaches to advance and enable smarter and faster peptide drug discovery. Therefore, we were eager to get started when presented with this exciting challenge “can you make a drug candidate that ticks all the boxes, i.e. potent in vivo efficacy, a long half-life and excellent physicochemical properties. Do it within a year!” With this aim, we exploited our innovative ML-based peptide drug discovery platform ‘streaMLine’ and demonstrated how the platform effectively facilitates accelerated development of novel peptide-based therapeutics. Did we succeed? Yes! And it has been a fun ride! Definitely some ups and downs along the way and many lengthy discussions with the project team. A total of 2688 peptides were synthesized, screened, and analyzed using the ML-guided approach to map out a solution space for generating GLP-1R agonists derived from the secretin backbone. We are happy to present the inner workings of our streaMLine drug discovery platform in the Journal of Medicinal Chemistry Kudos to the amazing team, (Jens Christian Nielsen,Claudia U. Hjørringgaard,Mads Mørup Nygaard, Anita Wester, Lisbeth Elster, Trine Porsgaard, Randi Bonke Mikkelsen, Silas Anselm Rasmussen, Andreas Nygaard Madsen, Morten Schlein, Niels V., Kristoffer Rigbolt). Thanks for making this project a success. If you are into some light summer reading, you can find the full story here: (https://lnkd.in/dsAm7UHE) #drugdiscovery #pushingboundaries #speed #quality

Want to learn how #metabolomics is used in #pharma? Be sure to attend this event in Cambridge on Nov 13th, would love to #connect and #catch up with you all! biocrates life sciences ag, Allumiqs

Are you attending #Tides2024 in Boston this week? 💡 We value your insights and invite you to join us at booth #419. James McAllister, Phil Shymanski and Brenda Karim are ready to explain how our PurePep solutions can elevate your peptide projects together. 💊Tow major trends transform the landscape of peptide therapeutics dramatically ⭐ Chemical or display screening platforms become state-of-the-art for target-based drug development, resulting in a significantly enriched preclinical pipeline. ⭐ The success of GLP-1 analogs for weight loss and obesity treatment is moon-shooting the pharmaceutical relevance of peptides, causing a shortage of external synthesis capacity. 👉🏽 The performance of novel drug development projects hinges on a seamless transition from screening to the clinics. A critical component is the synthetic in-house capability to rapidly scale up and improve peptide quality in parallel, along with the ability to adopt complex chemistry to advance the stability and efficacy of your lead compounds. ⏳ The clock is ticking. It's crucial to equip ourselves with the right manufacturing tools to stay ahead of the curve in peptide therapeutics. ' See you at booth #419.

Today, we unveiled a new company name: RyCarma Therapeutics!    The name RyCarma is a nod to our foundational work in establishing the therapeutic potential of Rycals®, our mission to apply these first-in-class small molecule drugs to urgent unmet needs, as well as our focus on addressing heart failure and ryanodine receptor 1-related myopathies (RYR1-RM).     We’re also excited to introduce several new members to our leadership team: Adam Rosenberg, Chief Executive Officer, Jonathan Alspaugh, President & Chief Strategy Officer, and Sanjay Jalota, Senior Vice President of Regulatory. Together, they bring a track record of success in leading biotech companies and guiding novel biological discoveries through drug development.    RyCals are allosteric modulators of ryanodine receptors (RyRs), ion channels critical in intracellular calcium management, cellular signaling and muscle contraction. Our drug discovery platform is the first to target RyRs by building on the pioneering work of our founder Dr. Andrew Marks, a globally recognized leader in RyR science.    To learn more about the newest chapter in our story, read our press release: https://lnkd.in/eDVakDf7   You can see our new look as well as find the latest details about the innovative science behind Rycals and our pipeline at www.rycarma.com. We are excited for the journey ahead and developing this novel class of therapeutics for patients.     #Biotechnology #RyR #HeartFailure #RYR1RM 

Drug Discovery Services Market Worth $41.3 billion by 2028 🔵𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞:https://lnkd.in/diXdYs_N The global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028. 🔵 𝐌𝐚𝐢𝐧 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: X-Chem, Inc. Quantori NanoCellect Biomedical, Inc.      FUJIFILM Cellular Dynamics, Inc    Iambic Therapeutics  Sygnature Discovery XtalPi Inc. Skyhawk Therapeutics    BPS Bioscience Inc.     Biocytogen  Anima Biotech   The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Active Motif Reaction Biology Kallyope NETZSCH Premier Technologies, LLC       o2h discovery      Structure Therapeutics     Terray Therapeutics Remix Therapeutics       Eureka Therapeutics, Inc    Neomorph, Inc.      Charnwood Discovery   ACEA Biosciences  Plexium   AnaSpec Eurofins DiscoverX HTG Molecular Diagnostics       Calibr-Skaggs Institute for Innovative Medicines        MBL International Corporation     GemPharmatech Belharra Therapeutics HotSpot Therapeutics, Inc.   Neuron23       Jubilant Biosys Limited        Cajal Neuroscience NanoImaging Services  Skills Alliance abcam BenevolentAI 

Ready for some groundbreaking insights? Join us at the Oligonucleotide Therapeutics and Delivery conference in London on September 9-10 to hear the inside scoop on Cardior’s $1.1 billion acquisition by Novo Nordisk! Thomas Thum, the visionary Founder, Chief Scientific Officer, and Chief Medical Officer of Cardior Pharmaceuticals GmbH, will take the stage to discuss ‘Non-Coding RNA-based Therapeutics at the Pulse of Heart Disease’. Here's what you'll learn: - The latest on the ongoing phase 2 trial in heart failure patients: Discover how the oligonucleotide R&D landscape is revolutionizing heart failure treatments. - Cardior Pharmaceuticals/pharma company interaction: What this means for strengthened RNA-based pipelines for chronic populations - Delving into further drug discovery pipelines in heart failure subgroups, where is research and funding still needed? This is your chance to gain exclusive insight from a pioneer in the field. Don’t miss out! 🎟️ Secure your ticket now!➡https://ow.ly/t4Ty50SyNNA #SAEMGPharma #Pharma #OligoTherapeutics #OligoResearch #NucleicAcidTherapeutics #GeneTherapy #RNAi #Biotechnology #PrecisionMedicine #PharmaInnovation #TherapeuticDevelopment #Biopharma #GeneticMedicine #MolecularBiology #OligoTx

Our update this morning, covered at Benzinga - Enveric Biosciences, Inc. Advances #NonHallucinogenic DMT Analog Drug With Promising Preclinical Results https://lnkd.in/e_YAn2eB

Drug Discovery Services Market Latest Statistics 2024 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dtcN7Umn The size of global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028 Companies From the Market Enanta Pharmaceuticals NGM Biopharmaceuticals Biocytogen XtalPi Inc. NanoCellect Biomedical, Inc.    X-Chem, Inc. FUJIFILM Cellular Dynamics, Inc Sygnature Discovery BPS Bioscience Inc. Iambic Therapeutics Carmot Therapeutics, Inc. Active Motif The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Structure Therapeutics   Antheia, Inc. Anima Biotech Genesis Therapeutics Reaction Biology Kallyope Ligand Pharmaceuticals      Remix Therapeutics o2h discovery NETZSCH Premier Technologies, LLC   Terray Therapeutics  Seismic Therapeutic Charnwood Discovery Flare Therapeutics Kumquat Biosciences Inc.      Plexium ACEA Biosciences AnaSpec Zephyr AI    Eurofins DiscoverX  Neomorph, Inc. Calibr-Skaggs Institute for Innovative Medicines      GemPharmatech MBL International Corporation   Neuron23 Cajal Neuroscience   Belharra Therapeutics

#TBCPartner RyCarma Therapeutics kicked off 2025 in a big way by introducing a new company name, leadership team and a new program in heart failure.    The name RyCarma references the company’s expertise in developing Rycals® — first-in-class small molecule drugs that repair leaky ion channels required for muscle function. For patients with heart failure, Rycals® have the potential to be the first treatment option that not only improve heart function but also alleviate the common symptom of skeletal muscle weakness.    Visit RyCarma’s website at www.rycarma.com to see their new look and keep up with their progress.

Wanted to circle back on #DACs (#Degrader-Antibody #Conjugates) as the Beacon team recently conducted further analysis into this exciting space. What Are DACs? DACs, similar to #ADCs, replace the cytotoxic payload with a small molecule protein degrader (like #PROTACs or #molecular glues) to drive protein #degradation. These innovative conjugates combine: ✅ A monoclonal antibody (#mAb) ✅ A #payload ✅ A chemical #linker Key Advantages: DACs are highly selective, targeting specific #antigens on cell surfaces. Once internalized, they enable #lysosomal degradation and the depletion of disease-causing proteins via the ubiquitin-proteasome system. Landscape Highlights: Beacon is currently tracking 33 DACs, with 83% added in 2024, reflecting a significant surge in interest. Some Key Innovators: 🔹Orum Therapeutics & Bristol Myers Squibb: ORM-6151 (Phase 1) 🔹Orum: ORM-5029 (Phase 1) 🔹Nurix & Pfizer: Preclinical 🔹Firefly Bio: Preclinical 🔹Xiling Pharmaceutical: Preclinical 🔹Chengdu Fendi Pharmaceutical: FD-005 (Preclinical) Notable Deals 💡 Feb 2024: Firefly Bio raises $94M in Series A financing. 💡 Nov 2023: BMS acquires ORM-6151 from Orum Therapeutics for $180M. 💡 Dec 2023: C4 Therapeutics, Inc. & Merck & Co collaborate on DAC development ($610M deal). 💡 Jul 2024: Orum Therapeutics & Vertex Pharmaceuticals sign a $945M license and option agreement. 💡 Sep 2023: Nurix & Seagen (now Pfizer) ink a $3.5B strategic collaboration for a DAC portfolio. 🔗 Want to Learn More? Explore the DAC landscape here: https://lnkd.in/eeDf32ZD Below is a great illustration by Cullgen Inc. showcasing how DACs are internalized. #TargetedProteinDegradation #Oncology #Innovation #Biopharma #Collaboration #SmallMolecules